Fannie Mae, Freddie Mac shares tumble after conservatorship comments
In recent stock transactions, Rafael Amado, President and Head of Global Oncology Research and Development at Zai Lab Ltd (NASDAQ:ZLAB), sold 7,541 American Depositary Shares (ADS) on April 2, 2025. These shares were sold at an average price of $35.894, amounting to a total of $270,676. The transaction comes as Zai Lab shares have shown remarkable strength, posting a 129% return over the past year, according to InvestingPro data.
The sale was part of a transaction to cover taxes related to the vesting of Restricted Share Units (RSUs). On the previous day, April 1, 2025, Amado acquired 19,523 ADSs upon the vesting of RSUs. Each ADS represents ten ordinary shares of the company. Following these transactions, Amado holds 42,816 ADSs directly.
These moves provide insight into the executive’s current holdings and financial maneuvers within Zai Lab, a pharmaceutical company focused on innovative therapies.
In other recent news, Zai Lab has been the focus of multiple analyst assessments and projections. Cantor Fitzgerald reiterated an Overweight rating, emphasizing the potential of Bemarituzumab as a growth driver, despite its current lack of investor attention compared to other products. This drug is undergoing Phase 3 trials, and positive outcomes could significantly impact Zai Lab’s future growth. Meanwhile, Scotiabank (TSX:BNS) initiated coverage on Zai Lab with a Sector Outperform rating and set a price target of $55 per share, citing the company’s global potential and strong product lineup as key factors. The analyst also projects Zai Lab to become cash flow positive by the fourth quarter of 2025, which could lower the company’s risk profile.
In contrast, BofA Securities downgraded Zai Lab from Buy to Neutral but raised the price target to $36.10. This adjustment reflects a tempered outlook due to the soft performance of certain products, although promising developments in the pipeline, such as VYVGART and AUGTYRO, were noted. BofA Securities also highlighted the potential of Optune for pancreatic cancer and the progress with KarXT and Bemarituzumab. These recent developments have captured the attention of investors, who are closely monitoring Zai Lab’s strategic positioning and product advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.